South San Francisco, CA, June 20, 2018 – Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in...
Lilly and CoLucid Pharmaceuticals Announce Agreement for Lilly To Acquire CoLucid
INDIANAPOLIS, IN and CAMBRIDGE, MA, January 18, 2017 – Eli Lilly and Company (NYSE: LLY) and CoLucid Pharmaceuticals, Inc. (Nasdaq: CLCD) today announced an agreement for Lilly to acquire CoLucid for $46.50 per share or approximately $960 million. This all-cash transaction will enhance Lilly’s existing portfolio in pain management for migraine, while adding a potential near-term launch to its late-stage pipeline.
© 2018 Pappas Capital, LLC. ALL RIGHTS RESERVED.